Stifel Canada Analysts Raise Earnings Estimates for TSE:CPH

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Equities researchers at Stifel Canada upped their FY2025 earnings estimates for shares of Cipher Pharmaceuticals in a research report issued to clients and investors on Tuesday, December 3rd. Stifel Canada analyst J. Keywood now forecasts that the company will post earnings per share of $0.98 for the year, up from their prior forecast of $0.97. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.02). The company had revenue of C$14.15 million during the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%.

Several other research firms also recently issued reports on CPH. Stifel Nicolaus reduced their price target on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a research report on Monday, November 11th. Leede Financial downgraded shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

TSE CPH opened at C$16.00 on Friday. The company has a fifty day simple moving average of C$15.42 and a 200 day simple moving average of C$13.02. Cipher Pharmaceuticals has a 12-month low of C$5.35 and a 12-month high of C$19.69. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The company has a market cap of C$409.44 million, a P/E ratio of 12.80 and a beta of 1.20.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.